UK’s NICE rejects use of Gilead’s Yescarta on NHS over cost concerns
The National Institute for Health and Care Excellence (NICE) has recommended against the use of Gilead’s Yescarta (axicabtagene ciloleucel) on…
Yescarta
-
-
Gilead’s Yescarta secures positive opinion from Europe’s CHMP
Gilead Sciences subsidiary Kite has secured a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
